VolitionRx Closes $6.9 Million Public Offering

Represented VolitionRx in a confidentially-marked underwritten public offering of common stock, including the exercise in full of the overallotment option, resulting in gross proceeds of $6.9 Million. Newbridge Securities Corporation acted as the sole book-running manager of the offer.

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients but also improve their quality of life. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.